PHAT Phathom Pharmaceuticals Inc

Price (delayed)

$6.985

Market cap

$565.09M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.26

Enterprise value

$894.49M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 39

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid ...

Highlights
The revenue has soared by 110% YoY and by 17% from the previous quarter
Phathom Pharmaceuticals's gross profit has soared by 101% YoY and by 14% from the previous quarter
The equity rose by 15% YoY but it fell by 2.2% QoQ
The quick ratio has declined by 17% year-on-year and by 13% since the previous quarter
The gross margin has declined by 4.6% year-on-year and by 2.4% since the previous quarter

Key stats

What are the main financial stats of PHAT

PHAT stock price

How has the Phathom Pharmaceuticals stock price performed over time
Intraday
-9.99%
1 week
-9.17%
1 month
-21.25%
1 year
-41.3%
YTD
-57.9%
QTD
-35.62%

Financial performance

How have Phathom Pharmaceuticals's revenue and profit performed over time
Revenue
$239.66M
Gross profit
$198.73M
Operating income
-$40.64M
Net income
-$99.07M
Gross margin
82.9%
Net margin
-41.3%
The revenue has soared by 110% YoY and by 17% from the previous quarter
Phathom Pharmaceuticals's gross profit has soared by 101% YoY and by 14% from the previous quarter
The operating margin has soared by 93% year-on-year and by 64% since the previous quarter
PHAT's net margin has surged by 86% year-on-year and by 46% since the previous quarter

Price vs fundamentals

How does PHAT's price correlate with its fundamentals

Growth

What is Phathom Pharmaceuticals's growth rate over time

Valuation

What is Phathom Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.73
The EPS has soared by 73% year-on-year and by 40% since the previous quarter
The equity rose by 15% YoY but it fell by 2.2% QoQ
The revenue has soared by 110% YoY and by 17% from the previous quarter
The price to sales (P/S) is 49% lower than the last 4 quarters average of 5.3

Efficiency

How efficient is Phathom Pharmaceuticals business performance
The ROS has soared by 93% year-on-year and by 67% since the previous quarter
The ROIC has soared by 86% YoY and by 60% from the previous quarter
Phathom Pharmaceuticals's ROA has soared by 65% YoY and by 41% from the previous quarter

Dividends

What is PHAT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PHAT.

Financial health

How did Phathom Pharmaceuticals financials performed over time
The total assets is 51% smaller than the total liabilities
The total assets is up by 31% year-on-year and by 7% since the previous quarter
The current ratio has contracted by 19% YoY and by 13% from the previous quarter
The equity rose by 15% YoY but it fell by 2.2% QoQ
The debt to equity has declined by 10% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.